Status:
RECRUITING
Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
Lead Sponsor:
Regina Elena Cancer Institute
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
Brief Summary
The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5...
Detailed Description
The esSBRT study ("Early salvage stereotactic radiotherapy (esSBRT) for biochemical recurrence after radical prostatectomy: a phase II study", RS1705/22 - opinion of the Central Ethics Committee IRCCS...
Eligibility Criteria
Inclusion
- patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same);
- patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing)
Exclusion
- all exclusion criteria adopted for the "esSBRT" study.
Key Trial Info
Start Date :
November 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 4 2027
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT06894628
Start Date
November 4 2024
End Date
November 4 2027
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCSS Regina Elena
Roma, Italy, 00144